Introduction {#s1}
============

Pancreatic cancer is predicted to be the second leading cause of cancer-related death by 2030 ([@B1]), and is frequently diagnosed at an advanced stage. To date, the etiology of pancreatic cancer is not well understood ([@B2]). Apart from smoking ([@B3]), long-standing diabetes ([@B4]), obesity and chronic pancreatitis ([@B5]), little is known about the risk factors and biological processes that lead to pancreatic cancer development ([@B6], [@B7]).

Recently, there has been mounting evidence that the humoral immune system plays a role in the development of pancreatic cancer. Epidemiological studies have suggested that viral and bacterial infections contribute to pancreatic cancer pathogenesis ([@B8]--[@B13]). Most studies focused on humoral responses to *Helicobacter pylori* and found contradicting results ([@B14]--[@B17]). More recently, periodontal disease, caused by bacterial infections of pathogens such as *Porphyromonas gingivalis* and *Fusobacterium species*, has been suggested to play a role in the development and prognosis of pancreatic cancer ([@B18]--[@B24]). Furthermore, other responses of the humoral immune system, such as allergic reactions, may present a protective effect for pancreatic cancer diagnosis ([@B25]--[@B29]).

In addition to the epidemiological studies, experimental studies have reported a number of antigens that are highly expressed in pancreatic cancer cells ([@B30], [@B31]). For example, significant levels of immunoglobulin (Ig) G antibodies have been detected in cancer patients\' plasma, including in pancreatic cancer patients. More specifically, anti-MUC1 serum IgG levels and IgG serum IgG4 concentrations (\>135 mg/dL) have been measured in patients with pancreatic cancer ([@B32]--[@B34]). In contrast, no data is available for other antibodies such as IgA and IgM in relation with pancreatic cancer.

Despite the growing evidence for a role of the humoral immune system in pancreatic cancer development, to our knowledge no epidemiological studies have yet evaluated the association between pre-diagnostic serum markers of the overall humoral immune response and risk of pancreatic cancer. A better understanding of the etiology and underlying biological mechanisms for pancreatic cancer may improve our ability to identify high risk individuals and improve early detection.

We therefore present the first large population-based prospective cohort study to examine pre-diagnostic markers of the overall humoral immune response (IgG, IgA, and IgM) in relation to pancreatic cancer.

Materials and Methods {#s2}
=====================

Study Population and Data Collection
------------------------------------

The Swedish Apolipoprotein-related MORtality RISk (AMORIS) cohort includes information from blood and urine samples for 812,073 subjects obtained and analyzed between 1985 and 1996. All laboratory analyses were conducted at the Central Automation Laboratory (CALAB), Stockholm. The subjects were residents of Sweden and were predominantly living in the Stockholm county, ranging in age from less than 20 to over 80 years old. All participants were either healthy individuals referred for clinical laboratory testing as part of health check-ups or outpatients referred for laboratory testing ([@B35]). A more detailed description of the AMORIS cohort is given elsewhere ([@B35]--[@B39]).

The AMORIS cohort has been followed via record linkage using the Swedish 10-digit personal identity number in Swedish national health registers, registers of quality of care, and surveys including socio-economic data as well as a questionnaire and biomedical data from number of research cohorts ([@B35]). For the purpose of the current study, the National Cancer Register, the Patient Register, the Cause of death Register and the consecutive Swedish Censuses during 1970--1990 have been utilized. This study complied with the Declaration of Helsinki and was approved by the Ethics Review Board of the Karolinska Institutet.

This study included all individuals aged 20 years or older who were free from pancreatic cancer at baseline, as registered in the National Cancer Register dating back to 1958. Furthermore, participants were excluded if they had a history of chronic pancreatitis, as defined in the National Patient Register going back nationally to 1987 and regionally to 1964. All subjects were required to have a baseline measurement of IgA or IgG or IgM measured at a health examination between 1985 and 1996. If a participant had multiple measurements of an immunoglobulin, the first measurement was included in the study to allow for consistency across the entire cohort. Follow-up time was defined as time from baseline measurement until date of cancer diagnosis, death, emigration, or end of the study (31st of December 2011), whichever occurred first.

The main outcome variable was a diagnosis of pancreatic cancer (International Classification of Diseases (ICD), Revision 7 (1955) code 157). We also included the following information from the AMORIS study: serum IgA (g/L), serum IgG (g/L), serum IgM (g/L), serum glucose (mmol/L), age at baseline measurement and gender. From the other registries, we collected information regarding education, Charlson Comorbidity Index (CCI) and socioeconomic status (SES).

The quantitative determination of IgA, IgG, and IgM was performed using turbidimetry with reagents (DAKO -- Glostrup, Denmark) using a HITACHI 911 automatic analyser (Boehringer -- Mannheim, Germany) with a coefficient of variation \<5% (IgA), ≤ 5% (IgG), and ≤ 7% (IgM) ([@B40]--[@B42]).

Data Analyses
-------------

We estimated the risk of pancreatic cancer with multivariate Cox proportional hazards regression for medical cut-offs used in the CALAB laboratory of IgG (\<6.10, 6.10--14.99, ≥15.00 g/L) ([@B41]). IgA was dichotomised as \<3.66 g/L and ≥3.66 g/L instead of the medical cut-offs (\<0.70, 0.70--3.65, ≥3.66 g/L) due to the small number of participants with low IgA levels ([@B40], [@B43]). Levels of IgM were dichotomised as \<1.40 g/L and ≥1.40 g/L, as proposed by the normal laboratory values for blood, plasma and serum from the MSD manual ([@B44]).

Multivariate Cox proportional hazards regression models were adjusted for age, gender, education, CCI and serum glucose level (continuous variable). A test for trend was conducted by using assignment to medical cut-offs as an ordinal scale for IgG. To assess reverse causation, a sensitivity analysis was conducted in which those who had a follow-up time \<1 year and \<3 years, respectively, were removed.

With regards to IgG, we performed stratified analyses for age (\<55 and ≥55), gender (male and female) and serum glucose levels (\<7.00 and ≥7.00 mmol/L). A *P*-value for interaction was calculated.

Finally, restrictive Cubic Spline (RCS) function was used to graphically display the hazard ratios representing the dose-response association between IgG and the risk of pancreatic cancer. We used knots located at the 5, 50, and 95th percentiles. This analysis was performed using the RCS_RegSAS Macro created by Desquibet and Mariotti ([@B45]). All statistical analyses were conducted with Statistical Analysis Systems (SAS) release 9.4 (SAS Institute, Cary, NC).

Results {#s3}
=======

Immunoglobulin G
----------------

Characteristics of study participants with a measurement of IgG are shown in [Table 1](#T1){ref-type="table"}. During a mean follow-up of 21.3 years, 689 participants developed pancreatic cancer. The mean age at measurement in participants who later developed pancreatic cancer was higher (55.8 years) than in participants without pancreatic cancer (47.1 years).

###### 

Descriptive statistics of study population with a measurement of IgG.

                                         **Pancreatic cancer *N* = 689 *n* (%)**   **No pancreatic cancer *N* = 135,532 *n* (%)**
  -------------------------------------- ----------------------------------------- ------------------------------------------------
  **Mean Age (years) (SD)**              55.8 (11.37)                              47.1 (14.33)
  \<55                                   319 (46.30)                               95,342 (70.35)
  ≥55                                    370 (53.70)                               40,190 (29.65)
  **Gender**                                                                       
  Men                                    388 (56.31)                               68,995 (50.91)
  Women                                  301 (43.69)                               66,537 (49.09)
  **SES**                                                                          
  Unclassified/missing                   74 (10.74)                                13,561 (10.01)
  Low                                    283 (41.07)                               59,611 (43,98)
  High                                   332 (48.19)                               62,360 (46.01)
  **Education**                                                                    
  Missing                                109 (15.82)                               8,594 (6.34)
  Low                                    211 (30.62)                               37,876 (27.95)
  Middle                                 241 (34.98)                               55,617 (41.04)
  High                                   128 (18.58)                               33,445 (24.68)
  **Charlson Comorbidity Index**                                                   
  0                                      622 (90.28)                               126,594 (93.41)
  1                                      49 (7.11)                                 6,265 (4.62)
  2                                      13 (1.89)                                 1,565 (1.15)
  3+                                     5 (0.73)                                  1,108 (0.82)
  **Mean follow-up time (years) (SD)**   13.1 (7.64)                               21.3 (6.67)
  **Glucose (mmol/L)**                                                             
  Mean (SD)                              5.34 (1.71)                               5.01 (1.28)
  \<5.60 mmol/L                          501 (72.71)                               107,538 (79.35)
  5.60--6.99 mmol/L                      107 (15.53)                               14,352 (10.59)
  ≥7.00 mmol/L                           48 (6.97)                                 4,040 (2.98)
  Missing                                33 (4.79)                                 9,602 (7.08)
  **IgG (g/L)**                                                                    
  Mean (SD)                              11.17 (2.77)                              11.55 (3.03)
  \<6.10 g/L                             14 (2.03)                                 1,493 (1.10)
  6.10--14.99 g/L                        601 (87.23)                               116,704 (86.11)
  ≥15.00 g/L                             74 (10.74)                                17,335 (12.79)

Multivariate Cox regression (adjusted for age, gender, education, CCI, and serum glucose level) for the association between immunoglobulin G and the risk of pancreatic cancer showed that, compared to the IgG reference level of 6.10--14.99 g/L, there was a positive association for those with IgG levels \<6.10 g/L \[HR: 1.69 (95% CI 0.99--2.87)\]. We also found an inverse association for those with IgG levels ≥15.00 g/L \[0.82 (95% CI 0.64--1.05); *P*trend = 0.027\] ([Table 2](#T2){ref-type="table"}). A sensitivity analysis to assess reverse causation by excluding those with follow-up time \<1 year and \<3 year did not affect the above findings (results not shown).

###### 

Hazard ratio (HR) for risk of pancreatic cancer, in the study population with a measurement of IgG, with 95% confidence intervals (CI) using Cox proportional hazards model.

                        **Pancreatic cancer/total *N***   **Hazard ratio[^a^](#TN2){ref-type="table-fn"} (95% CI)**
  --------------------- --------------------------------- -----------------------------------------------------------
  **IgG (g/L)**                                           
  \<6.10 g/L            14/1,507                          1.69 (0.99--2.87)
  6.10--14.99 g/L       601/117,305                       1.00 (ref)
  ≥15.00 g/L            74/17,409                         0.82 (0.64--1.05)
  *P*-value for trend                                     0.027

*Adjusted for age, gender, education, CCI, and serum glucose (continuous variable)*.

Stratified analysis by gender showed a similar inverse association between categories of IgG and the risk of developing pancreatic cancer. However, the strength of the association was more pronounced for women (P = 0.003) ([Table 3](#T3){ref-type="table"}). No effect modification by age and glucose levels was observed (results not shown). We further illustrated the association between serum IgG and the risk of developing pancreatic cancer through a dose-response curve with restrictive cubic splines ([Figure 1](#F1){ref-type="fig"}). The direction of the hazard ratios observed in [Tables 2](#T2){ref-type="table"}, [3](#T3){ref-type="table"} was consistent with shape of the curve, which presented a positive association for IgG levels lower than 11.00 g/L with pancreatic cancer risk and a protective effect for high levels of IgG (11.00−20.00 g/L).

###### 

Hazard ratio (HR) for risk of pancreatic cancer stratified by gender, in the study population with a measurement of IgG, with 95% confidence intervals from Cox proportional Hazards model.

                                **Hazard Ratio[^a^](#TN2){ref-type="table-fn"} (95% CI)**   
  ----------------------------- ----------------------------------------------------------- -------------------
  Pancreatic cancer/total (n)   388/69,383                                                  301/66,838
  IgG (g/L)                                                                                 
  \<6.10 g/L                    1.46 (0.65--3.27)                                           1.98 (0.97--4.00)
  6.10--14.99 g/L               1.00 (ref)                                                  1.00 (ref)
  ≥15.00 g/L                    0.95 (0.69--1.29)                                           0.64 (0.43--0.97)
  *P*-value for interaction     0.003                                                       

*Adjusted for age, education, CCI, and serum glucose (continuous variable)*.

![Adjusted dose-response association between serum levels of IgG (g/L) and risk of pancreatic cancer (HR) using restrictive cubic splines. The direction of the hazard ratios observed in [Tables 2](#T2){ref-type="table"}, [3](#T3){ref-type="table"} was consistent with the shape of the curve, which presents a positive association for IgG levels lower than 11.00 g/L with pancreatic cancer risk (HR \> 1.00) and a protective effect for high levels of IgG (11.00--20.00 g/L) (HR \<1.00). However, the inverse association was only statistically significant for concentrations of IgG between 11.00 and 16.00 g/L.](fonc-10-00263-g0001){#F1}

Immunoglobulin A and Immunoglobulin M
-------------------------------------

Characteristics of study participants with a measurement of IgA are shown in [Table 4](#T4){ref-type="table"}. During a mean follow-up of 16.5 years, 169 participants developed pancreatic cancer. Characteristics of study participants with a measurement of IgM are shown in [Table 5](#T5){ref-type="table"}. During a mean follow-up of 15.4 years, 117 participants developed pancreatic cancer.

###### 

Descriptive statistics of study population with a measurement of IgA.

                                         **Pancreatic cancer *N* = 169 *n* (%)**   **No pancreatic cancer *N* = 41,731 *n* (%)**
  -------------------------------------- ----------------------------------------- -----------------------------------------------
  **Mean Age (years) (SD)**              60.3 (12.07)                              49.6 (16.10)
  \<55                                   58 (34.32)                                27,142 (65.04)
  ≥55                                    111 (65.68)                               14,589 (34.96)
  **Gender**                                                                       
  Men                                    69 (40.83)                                14,999 (35.94)
  Women                                  100 (59.17)                               26,732 (64.06)
  **SES**                                                                          
  Unclassified/Missing                   27 (15.98)                                7,499 (17.97)
  Low                                    69 (40.83)                                18,137 (43.46)
  High                                   73 (43.20)                                16,095 (38.57)
  **Education**                                                                    
  Missing                                14 (8.28)                                 2,358 (5.65)
  Low                                    50 (29.59)                                10,787 (25.85)
  Middle                                 64 (37.87)                                17,734 (42.50)
  High                                   41 (24.26)                                10,852 (26.00)
  **Charlson Comorbidity Index**                                                   
  0                                      138 (81.66)                               37,290 (89.36)
  1                                      22 (13.02)                                2,950 (7.07)
  2                                      7 (4.14)                                  856 (2.05)
  3+                                     2 (1.18)                                  635 (1.52)
  **Mean follow-up time (years) (SD)**   8.8 (5.88)                                16.5 (5.22)
  **Glucose (mmol/L)**                                                             
  Mean (SD)                              5.50 (1.76)                               5.08 (1.42)
  \<5.60 mmol/L                          96 (56.80)                                25,481 (61.06)
  5.60--6.99 mmol/L                      25 (14.79)                                3,990 (9.56)
  ≥7.00 mmol/L                           11 (6.51)                                 1,315 (3.15)
  Missing                                37 (21.89)                                10,945 (26.23)
  **IgA (g/L)**                                                                    
  Mean (SD)                              2.47 (1.20)                               2.32 (1.20)
  \<3.66 g/L                             151 (89.35)                               37,228 (89.21)
  ≥3.66 g/L                              18 (10.65)                                4,503 (10.79)

###### 

Descriptive statistics of study population with a measurement of IgM.

                                         **Pancreatic cancer *N* = 117 *n* (%)**   **No pancreatic cancer *N* = 29,802 *n* (%)**
  -------------------------------------- ----------------------------------------- -----------------------------------------------
  **Mean Age (years) (SD)**              60.9 (11.76)                              50.8 (16.25)
  \<55                                   36 (30.77)                                18,613 (62.46)
  ≥55                                    81 (69.23)                                11,189 (37.54)
  **Gender**                                                                       
  Men                                    48 (41.03)                                10,852 (36.41)
  Women                                  69 (58.97)                                18,950 (63.59)
  **SES**                                                                          
  Unclassified/missing                   18 (15.38)                                5,675 (19.04)
  Low                                    51 (43.59)                                12,759 (42.81)
  High                                   48 (41.03)                                11,368 (38.15)
  **Education**                                                                    
  Missing                                8 (6.84)                                  1,658 (5.56)
  Low                                    37 (31.62)                                7,885 (26.46)
  Middle                                 43 (36.75)                                12,585 (42.23)
  High                                   29 (24.79)                                7,674 (25,75)
  **Charlson comorbidity index**                                                   
  0                                      88 (75.21)                                26,205 (87.93)
  1                                      20 (17.09)                                2,349 (7.88)
  2                                      6 (5.13)                                  697 (2.34)
  3+                                     3 (2.56)                                  551 (1.85)
  **Mean follow-up time (years) (SD)**   8.15 (5.53)                               15.4 (4.73)
  **Glucose (mmol/L)**                                                             
  Mean (SD)                              5.53 (1.59)                               5.19 (1.51)
  \<5.60 mmol/L                          60 (51.28)                                16,259 (54.56)
  5.60--6.99 mmol/L                      19 (16.24)                                3,140 (10.54)
  ≥7.00 mmol/L                           8 (6.84)                                  1,046 (3.51)
  Missing                                30 (25.64)                                9,357 (31.40)
  **IgM (g/L)**                                                                    
  Mean (SD)                              1.11 (0.72)                               1.28 (0.96)
  \<1.40 g/L                             90 (76.92)                                20,330 (68.22)
  ≥1.40 g/L                              27 (23.08)                                9,472 (31.78)

We found no association between immunoglobulin A or immunoglobulin M and the risk of pancreatic cancer ([Tables 6](#T6){ref-type="table"}, [7](#T7){ref-type="table"}).

###### 

Hazard ratio (HR) for risk of pancreatic cancer, in the study population with a measurement of IgA, with 95% confidence intervals (CI) using Cox proportional hazards model.

                  **Pancreatic cancer/total *N***   **Hazard ratio[^a^](#TN3){ref-type="table-fn"} (95% CI)**
  --------------- --------------------------------- -----------------------------------------------------------
  **IgA (g/L)**                                     
  \<3.66 g/L      151/37,379                        1.00 (ref)
  ≥3.66 g/L       18/4,521                          0.70 (0.39--1.26)

*Adjusted for age, education, CCI, and serum glucose (continuous variable)*.

###### 

Hazard ratio (HR) for risk of pancreatic cancer, in the study population with a measurement of IgM, with 95% confidence intervals (CI) using Cox proportional hazards model.

                  **Pancreatic cancer/total *N***   **Hazard ratio[^a^](#TN4){ref-type="table-fn"} (95% CI)**
  --------------- --------------------------------- -----------------------------------------------------------
  **IgM (g/L)**                                     
  \<1.40 g/L      90/20,420                         1.00 (ref)
  ≥1.40 g/L       27/9499                           0.82 (0.50--1.35)

*Adjusted for age, education, CCI, and serum glucose (continuous variable)*.

Discussion {#s4}
==========

In this project, we indicate the presence of an inverse association between serum IgG levels and the risk of developing pancreatic cancer in the Swedish AMORIS cohort. The inverse association was stronger in females compared with males. Pre-diagnostic serum levels of IgA or IgM did not show any association with the risk of pancreatic cancer.

The immune system has been thought to modulate the development and evolution of pancreatic cancer ([@B46]). Tobacco smoking, chronic pancreatitis, obesity and long-standing diabetes are established risk factors for pancreatic cancer ([@B4], [@B5], [@B47], [@B48]). All these risk factors can influence the immune response, induce the formation of pre-malignant lesions and stimulate pancreatic cancer development ([@B49], [@B50]). Pancreatic cancer tissue contains multiple immunosuppressive cell types, suggesting an impairment of the immune response in the tumor micro-environment ([@B50]). Evidence is growing for the role of the tumor-infiltrating B cells in the initiation and progression of pancreatic cancer ([@B51]). Tanaka et al., among other groups, also identified high serum levels of IgG on advanced pancreatic patients indicating IgG as a potential diagnostic test for pancreatic cancer ([@B52]).

Recent experimental and epidemiological data suggest the importance of the microbiome in pancreatic cancer development and its potential use as a marker of disease susceptibility ([@B9], [@B49], [@B53], [@B54]). Kau et al. highlighted the close interplay between life-style factors, such as diet and nutritional status, with the microbial ecology in the humans digestive system and its modulation of the immune system ([@B55]). Moreover, there is increasing evidence of the influence of the microbiota in the development of human diseases such as obesity and diabetes, established risks factors for pancreatic cancer ([@B56], [@B57]). More specifically, exposure to the bacterium *Helicobacter Pylori* is suggested as a risk factor for pancreatic cancer ([@B14]--[@B17]). Data also suggest a positive association between periodontal disease, due to an infection of the periodontal bacterium *Porphyromonas gingivalis and Fusobacterium species*, and pancreatic cancer risk ([@B8], [@B18]--[@B23]). The microbiota immune modulation promoting cancer pathogenesis has been explained through inflammatory processes in the tumor tissue, however it has also been shown in mice that bacteria not present in the tumorigenic tissue can promote carcinogenesis, nor do they need to cause inflammation in the tumor microenvironment ([@B8], [@B58]). New studies should further explore the interplay between lifestyle factors, microbiota and dysregulation of the immune system, which could provide new avenues to better understand the etiology of pancreatic cancer.

To our knowledge, this study is the first cohort that prospectively evaluate the association between pre-diagnostic serum markers of the overall humoral immune response and risk of pancreatic cancer. The observed inverse association between serum IgG and the risk of developing pancreatic cancer is consistent with the work by Michaud et al. ([@B20]): in a cluster analysis on oral bacteria antibodies, the cluster with overall higher levels of antibodies against 25 oral bacteria had a 45% lower risk of pancreatic cancer development than a cluster with overall lower levels of antibodies. This finding suggest that higher levels of antibodies against oral bacteria may reflect a stronger immune status which could have beneficial impact on reducing the risk of pancreatic cancer ([@B20]). Moreover, experimental studies found a similar protective effect for increased levels of IgG. Hamanaka et al., found circulating IgG antibodies to be a favorable prognostic factor for pancreatic cancer ([@B59]). In a recent publication, Follia et al. presented novel metabolic subtypes in pancreatic cancer and observed that the high immune infiltrated tumors had a better prognosis ([@B60]).

Regarding the stronger inverse association observed between IgG levels and pancreatic cancer, presented in women in our study, we suggest that this may indicate that sex is an effect modifier in this association given the differential distribution of immunoglobulin levels between sex that has been described previously ([@B43]).

The Swedish AMORIS cohort is one of the largest prospective cohort studies with detailed information on a range of serum biomarkers, including large number of baseline measurements of serum markers of the humoral immune system, all measured at the same clinical laboratory ([@B61]) at baseline health examinations during the period 1985--1996. The cohort has a 30+ year follow-up in Swedish national registers, including the Cancer, Patient, Census and Cause-of-Death registers, as well as quality registers for specific cancer sites. All participants of the AMORIS study were included by analysing blood and/or urine samples from health check-ups in non-hospitalized persons ([@B62]). However, any healthy cohort effect would not affect the internal validity of our study. The external validity of the study is not compromised given that the cancer incidence in the AMORIS population is comparable to the reported incidence in the Swedish population ([@B35]).

It was a limitation that immunoglobulin E (IgE), a serum biomarker of allergies studied previously in relation with pancreatic cancer ([@B63]), was only measured for a small subset of participants, so that it could not be assessed in relation to risk of pancreatic cancer. In addition, repeated measurements would have been helpful to verify the lag time between changes in markers of the humoral immune system and risk of pancreatic cancer. However, most of the individuals did not have multiple measurements. Information on other possible confounders such as BMI and smoking status was not available on AMORIS, therefore all models were adjusted for Charlson Comorbidity Index as a proxy for lifestyle factors. Biological material was unfortunately not available for further analyses. Molecular pathological analyses, such as the presence of immune cell infiltrates on the tumor tissue samples, can be an important resource in future studies to explore the potential association of the immune system, microbiome, lifestyle factors and pancreatic cancer development and to validate the epidemiological findings.

Conclusion {#s5}
==========

To our knowledge, this study is the first prospective cohort study evaluating the association between pre-diagnostic serum markers of the overall humoral immune response and the risk of pancreatic cancer. We observed an inverse association between pre-diagnostic serum levels of IgG and the risk of pancreatic cancer. Our findings highlight the need to investigate the roles of different components of humoral immunity and agents that may cause a humoral immune response related to pancreatic cancer. Future studies could provide further insight into potential biological mechanisms by exploring longitudinal data such as repeated measurements of pre-diagnostic serum markers of the humoral immune system. Moreover, molecular pathological epidemiological studies, exploring tumor tissues, can potentially untangle the interlink between lifestyle factors, microbiome, carcinogenesis and the immune system ([@B64]--[@B66]).
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